Phase II study of tamoxifen, ifosfamide, epirubicin and cisplatin combination chemotherapy in patients with non-small cell lung cancer failing previous chemotherapy

Yuh Min Chen, Reury Perng Perng, Kuang Young Yang, Wei Chun Lin, Hsiao Wei Wu, Chun Ming Tsai, Jacqueline Whang-Peng

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

We conducted a phase II study of tamoxifen, ifosfamide, epirubicin, and cisplatin (TIEP) chemotherapy in patients with non-small cell lung cancer (NSCLC) who had failed previous chemotherapy, in order to assess the response and toxicity of TIEP. Between November 1997 and May 1999, 25 patients were treated. Twelve of the 25 patients (48%) had been previously treated with cisplatin-based combination chemotherapy. TIEP doses were tamoxifen 60 mg oral twice daily on days 1-3; ifosfamide 2.4 g/m2 intravenous infusion (IV) 60 min with mesna on day 2; epirubicin 40 mg/m2 IV bolus on day 2; and cisplatin 50 mg/m2 IV 60 min on day 2 every 4 weeks for up to six cycles. Seventy one cycles were given to 25 patients, with a median of three cycles (range one to six cycles). All patients were evaluable for toxicity profile and response rate. As expected, the major toxicity was myelosuppression. Grade 3 or 4 neutropenia occurred in 15 patients (60%) during treatment, as well as in 31% of the total courses. Febrile neutropenia occurred in two patients. No toxic death occurred in this study. Grade 3 thrombocytopenia occurred in five patients with five cycles. Toxicities other than myelosuppression were few and mild in severity. After two cycles of treatment, five of 25 patients (20%) had a partial response (95% confidence interval 4.3-35.7%). Among 12 patients previously treated with cisplatin- based chemotherapy, three patients (25%) achieved a partial response. The median time to disease progression was 4.9 months and median survival was 7.7 months. The response rate and median survival were better than in our previous study of salvage chemotherapy with ifosfamide, 5-FU, and leucovorin; and with ifosfamide, epirubicin, 5-FU, and leucovorin. In conclusion, TIEP appears to be an active combination regimen with an acceptable toxicity profile in Chinese patients with NSCLC who have failed previous chemotherapy. (C) 2000 Elsevier Science Ireland Ltd.

Original languageEnglish
Pages (from-to)139-146
Number of pages8
JournalLung Cancer
Volume29
Issue number2
DOIs
Publication statusPublished - Aug 1 2000
Externally publishedYes

Fingerprint

Epirubicin
Ifosfamide
Tamoxifen
Combination Drug Therapy
Non-Small Cell Lung Carcinoma
Cisplatin
Drug Therapy
Intravenous Infusions
Leucovorin
Fluorouracil
Mesna
Febrile Neutropenia
Poisons
Neutropenia
Disease Progression
Survival Rate

Keywords

  • Cisplatin
  • Epirubicin
  • Ifosfamide
  • Non-small cell lung cancer
  • Salvage chemotherapy
  • Tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Phase II study of tamoxifen, ifosfamide, epirubicin and cisplatin combination chemotherapy in patients with non-small cell lung cancer failing previous chemotherapy. / Chen, Yuh Min; Perng, Reury Perng; Yang, Kuang Young; Lin, Wei Chun; Wu, Hsiao Wei; Tsai, Chun Ming; Whang-Peng, Jacqueline.

In: Lung Cancer, Vol. 29, No. 2, 01.08.2000, p. 139-146.

Research output: Contribution to journalArticle

Chen, Yuh Min ; Perng, Reury Perng ; Yang, Kuang Young ; Lin, Wei Chun ; Wu, Hsiao Wei ; Tsai, Chun Ming ; Whang-Peng, Jacqueline. / Phase II study of tamoxifen, ifosfamide, epirubicin and cisplatin combination chemotherapy in patients with non-small cell lung cancer failing previous chemotherapy. In: Lung Cancer. 2000 ; Vol. 29, No. 2. pp. 139-146.
@article{5be258b9104345a7a93ecfaf18374df4,
title = "Phase II study of tamoxifen, ifosfamide, epirubicin and cisplatin combination chemotherapy in patients with non-small cell lung cancer failing previous chemotherapy",
abstract = "We conducted a phase II study of tamoxifen, ifosfamide, epirubicin, and cisplatin (TIEP) chemotherapy in patients with non-small cell lung cancer (NSCLC) who had failed previous chemotherapy, in order to assess the response and toxicity of TIEP. Between November 1997 and May 1999, 25 patients were treated. Twelve of the 25 patients (48{\%}) had been previously treated with cisplatin-based combination chemotherapy. TIEP doses were tamoxifen 60 mg oral twice daily on days 1-3; ifosfamide 2.4 g/m2 intravenous infusion (IV) 60 min with mesna on day 2; epirubicin 40 mg/m2 IV bolus on day 2; and cisplatin 50 mg/m2 IV 60 min on day 2 every 4 weeks for up to six cycles. Seventy one cycles were given to 25 patients, with a median of three cycles (range one to six cycles). All patients were evaluable for toxicity profile and response rate. As expected, the major toxicity was myelosuppression. Grade 3 or 4 neutropenia occurred in 15 patients (60{\%}) during treatment, as well as in 31{\%} of the total courses. Febrile neutropenia occurred in two patients. No toxic death occurred in this study. Grade 3 thrombocytopenia occurred in five patients with five cycles. Toxicities other than myelosuppression were few and mild in severity. After two cycles of treatment, five of 25 patients (20{\%}) had a partial response (95{\%} confidence interval 4.3-35.7{\%}). Among 12 patients previously treated with cisplatin- based chemotherapy, three patients (25{\%}) achieved a partial response. The median time to disease progression was 4.9 months and median survival was 7.7 months. The response rate and median survival were better than in our previous study of salvage chemotherapy with ifosfamide, 5-FU, and leucovorin; and with ifosfamide, epirubicin, 5-FU, and leucovorin. In conclusion, TIEP appears to be an active combination regimen with an acceptable toxicity profile in Chinese patients with NSCLC who have failed previous chemotherapy. (C) 2000 Elsevier Science Ireland Ltd.",
keywords = "Cisplatin, Epirubicin, Ifosfamide, Non-small cell lung cancer, Salvage chemotherapy, Tamoxifen",
author = "Chen, {Yuh Min} and Perng, {Reury Perng} and Yang, {Kuang Young} and Lin, {Wei Chun} and Wu, {Hsiao Wei} and Tsai, {Chun Ming} and Jacqueline Whang-Peng",
year = "2000",
month = "8",
day = "1",
doi = "10.1016/S0169-5002(00)00106-9",
language = "English",
volume = "29",
pages = "139--146",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Phase II study of tamoxifen, ifosfamide, epirubicin and cisplatin combination chemotherapy in patients with non-small cell lung cancer failing previous chemotherapy

AU - Chen, Yuh Min

AU - Perng, Reury Perng

AU - Yang, Kuang Young

AU - Lin, Wei Chun

AU - Wu, Hsiao Wei

AU - Tsai, Chun Ming

AU - Whang-Peng, Jacqueline

PY - 2000/8/1

Y1 - 2000/8/1

N2 - We conducted a phase II study of tamoxifen, ifosfamide, epirubicin, and cisplatin (TIEP) chemotherapy in patients with non-small cell lung cancer (NSCLC) who had failed previous chemotherapy, in order to assess the response and toxicity of TIEP. Between November 1997 and May 1999, 25 patients were treated. Twelve of the 25 patients (48%) had been previously treated with cisplatin-based combination chemotherapy. TIEP doses were tamoxifen 60 mg oral twice daily on days 1-3; ifosfamide 2.4 g/m2 intravenous infusion (IV) 60 min with mesna on day 2; epirubicin 40 mg/m2 IV bolus on day 2; and cisplatin 50 mg/m2 IV 60 min on day 2 every 4 weeks for up to six cycles. Seventy one cycles were given to 25 patients, with a median of three cycles (range one to six cycles). All patients were evaluable for toxicity profile and response rate. As expected, the major toxicity was myelosuppression. Grade 3 or 4 neutropenia occurred in 15 patients (60%) during treatment, as well as in 31% of the total courses. Febrile neutropenia occurred in two patients. No toxic death occurred in this study. Grade 3 thrombocytopenia occurred in five patients with five cycles. Toxicities other than myelosuppression were few and mild in severity. After two cycles of treatment, five of 25 patients (20%) had a partial response (95% confidence interval 4.3-35.7%). Among 12 patients previously treated with cisplatin- based chemotherapy, three patients (25%) achieved a partial response. The median time to disease progression was 4.9 months and median survival was 7.7 months. The response rate and median survival were better than in our previous study of salvage chemotherapy with ifosfamide, 5-FU, and leucovorin; and with ifosfamide, epirubicin, 5-FU, and leucovorin. In conclusion, TIEP appears to be an active combination regimen with an acceptable toxicity profile in Chinese patients with NSCLC who have failed previous chemotherapy. (C) 2000 Elsevier Science Ireland Ltd.

AB - We conducted a phase II study of tamoxifen, ifosfamide, epirubicin, and cisplatin (TIEP) chemotherapy in patients with non-small cell lung cancer (NSCLC) who had failed previous chemotherapy, in order to assess the response and toxicity of TIEP. Between November 1997 and May 1999, 25 patients were treated. Twelve of the 25 patients (48%) had been previously treated with cisplatin-based combination chemotherapy. TIEP doses were tamoxifen 60 mg oral twice daily on days 1-3; ifosfamide 2.4 g/m2 intravenous infusion (IV) 60 min with mesna on day 2; epirubicin 40 mg/m2 IV bolus on day 2; and cisplatin 50 mg/m2 IV 60 min on day 2 every 4 weeks for up to six cycles. Seventy one cycles were given to 25 patients, with a median of three cycles (range one to six cycles). All patients were evaluable for toxicity profile and response rate. As expected, the major toxicity was myelosuppression. Grade 3 or 4 neutropenia occurred in 15 patients (60%) during treatment, as well as in 31% of the total courses. Febrile neutropenia occurred in two patients. No toxic death occurred in this study. Grade 3 thrombocytopenia occurred in five patients with five cycles. Toxicities other than myelosuppression were few and mild in severity. After two cycles of treatment, five of 25 patients (20%) had a partial response (95% confidence interval 4.3-35.7%). Among 12 patients previously treated with cisplatin- based chemotherapy, three patients (25%) achieved a partial response. The median time to disease progression was 4.9 months and median survival was 7.7 months. The response rate and median survival were better than in our previous study of salvage chemotherapy with ifosfamide, 5-FU, and leucovorin; and with ifosfamide, epirubicin, 5-FU, and leucovorin. In conclusion, TIEP appears to be an active combination regimen with an acceptable toxicity profile in Chinese patients with NSCLC who have failed previous chemotherapy. (C) 2000 Elsevier Science Ireland Ltd.

KW - Cisplatin

KW - Epirubicin

KW - Ifosfamide

KW - Non-small cell lung cancer

KW - Salvage chemotherapy

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=0033837675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033837675&partnerID=8YFLogxK

U2 - 10.1016/S0169-5002(00)00106-9

DO - 10.1016/S0169-5002(00)00106-9

M3 - Article

C2 - 10963844

AN - SCOPUS:0033837675

VL - 29

SP - 139

EP - 146

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2

ER -